Pharmacokinetics of Clozapine: An Investigate the Potential Molecular Mechanisms of Action

Journal of Chemical Health Risks

مقاله 12، دوره 12، شماره 2، شهریور 2022، صفحه 247-254   

نوع مقاله: Mini Review Article

شناسه دیجیتال (DOI): 10.22034/jchr.2021.1941063.1415

نویسندگان

Vajagathali M؛ Iyshwarya B.K؛ Ramakrishnan V^*

Human Cytogenetics and Genomics Laboratory, Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamilnadu, India

چکیده

Pharmacological surveillance research has usually focused on maintaining chronic experience to marginally efficient blood levels to manage adherence and prevent withdrawal symptoms. The reasoning to use targeted therapies checking in regards to atypical antipsychotics is being discussed, at least in the context of its actual therapeutic efficacy. However, there is proof that it can enhance utility, particularly when psychotic individuals do not react or improve adverse effects while using an effective dose. Moreover, plasma drug levels identifications may be helpful in medical-legal conditions. This study focused on the therapeutic pharmacokinetic information for clozapine and briefly discussed the relationship with plasma levels. Clozapine research showed a link between plasma levels and therapeutic signs, with a 350–420 m m^-1limit related to positive therapeutic outcomes. Since elevated plasma concentration levels of clozapine can raise the threat of epilepsy, targeted therapies surveillance is well defined. Several components impact plasma clozapine levels, including modified cytochrome P450 1A4 action, age, sex, and cigarette smoking. 

کلیدواژه‌ها

Pharmacokinetics؛ Clozapine؛ Atypical antipsychotics؛ Cytochrome؛ Therapeutics

مراجع

1.Brodie B.B., 1965. Displacement of one drug by another from carrier or receptor sites. Proc R Soc Med. 58, 946–55.

2.McCutcheon R., Beck K., D’Ambrosio E., Donocik J., Gobjila C., Jauhar S., Kaar S., Pillinger T., Reis Marques T., Rogdaki M., Howes O.D., 2018. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. ActaPsychiatr Scand. 137(1), 39–46.

3.Buur-Rasmussen B., Brosen K., 1999. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol. 9, 453–9.

4.Prior T.I., Chue P.S., Tibbo P., Baker G.B., 1999. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol.9, 301–9.

5.Mauri M.C., Volonteri L., Dell’Osso B., Regispani F., Papa P., Baldi M.L., Bareggi S.R., 2003. Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol. 23(6), 660–4.

6.Steen N.E., Aas M., Simonsen C., Dieset I., Tesli M., Nerhus M., Gardsjord E., Mørch R., Agartz I., Melle I., Ueland T., Spigset O., Andreassen O.A., 2017. Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders. World J Biol Psychiatry. 18(6), 471–82.

7.Preskorn S.H., 2014. Therapeutic drug monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don’t work. J Psychiatr Pract. 20(2), 133–7.

8.Hiemke C., Bergemann N., Clement H.W., Conca A., Deckert J., Domschke K., Eckermann G., Egberts K., Gerlach M., Greiner C., Gründer G., 2018. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry. 51(1–02), 9–62.

9.Meltzer H.Y., Bastani B., Ramirez L., Matsubara S., 1989. Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci. 238, 332–9.

10.Meltzer H.Y., 1982. The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press Ltd. pp. 1–13.

11.Perry P.J., Miller D.D., Arndt S.V., Cadoret R.J., 1991. Clozapine and norclozapine plasma concentrations and clinical response treatment-refractory schizophrenic patients. Am J Psychiatry. 148, 231–5.

12.Hasegawa M., Gutierrez-Esteinou R., Way L., Meltzer H.Y., 1993. Relationship between clinical efficacy and clozapine concentration in plasma in schizophrenia: effect of smocking. J Clin Psychopharmacol. 13, 383–90.

13.Potkin S.G., Bera R., Gulasekaram B., Costa J., Hayes S., Jin Y., Richmond G., Carreon D., Sitanggan K., Gerber B., Telford J., Plon L., Plon H., Park L., Chang Y.J., Oldroyd J., Cooper T., 1994. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 55, 133–6.

14.Kronig M.H., Munne R.A., Szymansky S., Safferman A.Z., Pollack S., Cooper T., Kane J.M., Lieberman J.A., 1995. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 152, 179–82.

15.Mauri M.C., Volonteri L.S., Fiorentini A., Invernizzi G., Bareggi S.R., 2004. Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr Res. 66,197–8.

16. Freeman D.J., Oyewumi L.K.,1997. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet.32, 95–100.

17.Khan A.Y., Preskorn S.H., 2005. Examining concentration-dependence toxicity of clozapine: role of therapeutic drug monitoring. J Psychiat Pract. 11, 289–301.

18.Ackenheil V.M., Brau H., Burkhart A., Franke A., Pacha W., 1976. Antipsychotic efficacy in relation to plasma levels of clozapine. Arzneimttelforschung. 26, 1156–8.

19.Thorup M., Fog R., 1977. Clozapine treatment of schizophrenic patients: plasma concentration and coagulation factors. Acta Psychiatr Scand. 66, 123–6.

20.Brau V.H., Burkhart A., Pacha W., Ackenheil V.M., 1978. Relationships between effects and plasma levels of clozapine. Arzneimttelforschung. 28, 1300.

21.Bell R., Mc Laren A., Galanos J., Copolov D., 1998. The clinical use of plasma clozapine levels. Aust N Z J Psychiatry. 32, 567–74.

22.Volpicelli S.A., Centorrino F., Puopolo P.R., Kando J., Frankenburg F.R., Baldessarrini R.J., Flood J.G., 1993. Determination of clozapine, norclozapine and clozapine-N-oxide in serum by liquid chromatography. Clin Chem. 39, 1656–9.

23.Palego L., Biondi L., Giannaccini G., Sarno N., Elmi S., Ciapparelli A., Cassano G.B., Lucacchini A., Martini C., Dell’Osso L., 2002. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients. Influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry. 26, 473–80.

24.Jann M.W., Grimsley S.R., Gray E.C., Chang W.H., 1993. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinetic. 24, 161–76.

25.Choc M.G., Lehr R.G., Hsuan F., Honigfeld G., Smith H.T., Borison R., Volavka J., 1987. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res. 4, 402–5.

26.Choc M.G., Hsuan F., Honigfeld G., Robinson W.T., Ereshefsky L., Crismon M.L., Saklad S.R., Hirschowitz J., Wagner R., 1990. Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res. 7, 347–51.

27.Blackman G., Lisshammar J.E., Zafar R., Pollak T.A., Pritchard M., Cullen A.E., Rogers J., Carter B., Griffiths K., Nour M., David A.S., 2021Clozapine Response in Schizophrenia and Hematological Changes. Journal of Clinical Psychopharmacology. 41(1), 19.

28.Tan M.S., Honarparvar F., Falconer J.R., Parekh H.S., Pandey P., Siskind D.J., 2021. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. Psychopharmacology. 7, 1-23.

29.Fabrazzo M., La Pia S., Monteleone P., Esposito G., Pinto A., De Simone L., Bencivenga R., Maj M., 2002. Is the time corse of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology. 27:1050–5.

30.Miller D.D., Fleming F., Holman T.L., Perry P., 1994. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry. 55,117–21.

31.Schulte P., 2003. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet. 42, 607–18.

32.Eap C.B., Bender S., Jaquenoud S.E., Cucchia G., Jonzier-Perey M., Baumann P., Allorge D., Broly F., 2004. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 24, 214–9.

33.Akamine Y., Sugawara-Kikuchi Y., Uno T., Shimizu T., Miura M., 2017. Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. Ann Clin Biochem. 54(6), 677–85.

34.To 'the K., Csukly G., Sirok D., Belic A., Kiss A., Ha' fra E., De' ri M., Menus A., Bitter I., Monostory K., 2017. Potential role of patients’ CYP3A-status in clozapine pharmacokinetics. Int J Neuropsychopharmacol. 20(7), 529–37.

35.Wohkittel C., Gerlach M., Taurines R., Wewetzer C., Unterecker S., Burger R., Schreck D., Mehler-Wex C., Romanos M., Egberts K., 2016. Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice. J Neural Transm (Vienna). 123(8), 1021–31.

36.Nordstrom A.L., Farde L., Nyberg S., Karlsson P., Halldin C., Sedvall G., 1995. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry. 152,1444–9.

37.Seeman P., Van Tool H.H.M., 1995. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol Mol Pharmacol. 291, 59–66.

38.Zhao A.L., Zhao J.P., Zhang Y.H., Xue Z.M., Chen J.D., Chen X.G., 2005. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci. 115, 1539–47.

39.Molins C., Carceller-Sindreu M., Navarro H., Carmona C., Pin ˜eiro M., Martı ´nez E., A ´lvarez E., Portella M.J., 2017. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients. Psychiatry Res. 258,153–7.